Johnson & Johnson announced the acquisition of Intra-Cellular Therapies for $14.6 billion, enhancing its neuroscience portfolio. This strategic move focuses on Caplyta, an antipsychotic drug for bipolar disorder and schizophrenia, which could significantly boost J&J’s revenue. The deal aims to capitalize on the growing mental health therapeutics market. Listen ⇢